"RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma." by Prakash Chinnaiyan

Article

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

International Journal of Radiation Oncology Biology Physics (2013)

Prakash Chinnaiyan, University of Wisconsin-Madison
Minhee Won, Radiation Therapy Oncology Group
Patrick Y. Wen, Brigham and Women's Hospital
Amyn M. Rojiani, Georgia Regents University
Merideth Wendland, Willamette University
Thomas A. Dipetrillo, Brown University
Benjamin W. Corn, Thomas Jefferson University
Minesh P. Mehta, University of Maryland, Baltimore

Link

Disciplines

Publication Date

January 8, 2013

DOI

10.1016/j.ijrobp.2013.04.036

Citation Information

Prakash Chinnaiyan, Minhee Won, Patrick Y. Wen, Amyn M. Rojiani, et al.. "RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma." International Journal of Radiation Oncology Biology Physics Vol. 86 Iss. 5 (2013) p. 880 - 884
Available at: http://works.bepress.com/minesh-mehta/246/